Abstract
Modulation of DNA repair pathways in oncology has been an area of intense interest in the last decade, not least as a consequence of the promising clinical activity of poly(ADP-ribose) polymerase (PARP) inhibitors. In this review article, we highlight inhibitors of the phosphatidylinositol 3-kinase related kinase (PIKK) family as of potential interest in the treatment of cancer, both in combination with DNA-damaging therapies and as stand-alone agents.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Ataxia Telangiectasia Mutated Proteins
-
Cell Cycle Proteins / antagonists & inhibitors
-
Cell Cycle Proteins / metabolism
-
DNA / metabolism
-
DNA Repair / drug effects*
-
DNA-Activated Protein Kinase / antagonists & inhibitors
-
DNA-Activated Protein Kinase / metabolism
-
DNA-Binding Proteins / antagonists & inhibitors
-
DNA-Binding Proteins / metabolism
-
Humans
-
Models, Molecular
-
Neoplasms / drug therapy*
-
Neoplasms / enzymology*
-
Neoplasms / metabolism
-
Protein Kinase Inhibitors / chemistry*
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Kinase Inhibitors / therapeutic use
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Protein Serine-Threonine Kinases / metabolism
-
Tumor Suppressor Proteins / antagonists & inhibitors
-
Tumor Suppressor Proteins / metabolism
Substances
-
Cell Cycle Proteins
-
DNA-Binding Proteins
-
Protein Kinase Inhibitors
-
Tumor Suppressor Proteins
-
DNA
-
ATM protein, human
-
ATR protein, human
-
Ataxia Telangiectasia Mutated Proteins
-
DNA-Activated Protein Kinase
-
Protein Serine-Threonine Kinases